Kuros Biosciences AG (CSBTF)
USD 32.4
(3.09%)
USD 32.4
(3.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 41.66 Million CHF | 51.51% |
| 2022 | 24.21 Million CHF | 28.58% |
| 2021 | 18.83 Million CHF | 41.07% |
| 2020 | 13.35 Million CHF | 18.01% |
| 2019 | 11.31 Million CHF | 2.6% |
| 2018 | 11.02 Million CHF | -2.21% |
| 2017 | 11.27 Million CHF | -49.68% |
| 2016 | 22.4 Million CHF | 336.1% |
| 2015 | 5.13 Million CHF | -47.76% |
| 2014 | 9.83 Million CHF | -59.47% |
| 2013 | 24.26 Million CHF | 66.26% |
| 2012 | 14.59 Million CHF | -31.43% |
| 2011 | 21.28 Million CHF | -18.8% |
| 2010 | 26.21 Million CHF | -27.88% |
| 2009 | 36.34 Million CHF | -16.66% |
| 2008 | 43.61 Million CHF | 56.83% |
| 2007 | 27.8 Million CHF | 11.05% |
| 2006 | 25.04 Million CHF | -25.64% |
| 2005 | 33.67 Million CHF | 19.04% |
| 2004 | 28.28 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.46 Million CHF | -33.26% |
| 2024 Q2 | 14.46 Million CHF | 0.0% |
| 2023 FY | 36.68 Million CHF | 51.51% |
| 2023 Q2 | 15.01 Million CHF | 125.61% |
| 2023 Q1 | 6.65 Million CHF | -50.14% |
| 2023 Q4 | 21.67 Million CHF | 89.22% |
| 2023 Q3 | 11.45 Million CHF | -23.74% |
| 2022 Q1 | 5.26 Million CHF | -47.83% |
| 2022 FY | 24.21 Million CHF | 28.58% |
| 2022 Q4 | 13.35 Million CHF | 82.54% |
| 2022 Q3 | 7.31 Million CHF | -31.68% |
| 2022 Q2 | 10.7 Million CHF | 103.19% |
| 2021 FY | 18.83 Million CHF | 41.07% |
| 2021 Q3 | 2.76 Million CHF | -67.35% |
| 2021 Q4 | 10.1 Million CHF | 265.88% |
| 2021 Q2 | 8.45 Million CHF | 103.17% |
| 2021 Q1 | 4.16 Million CHF | -11.5% |
| 2020 Q3 | 3.37 Million CHF | -46.36% |
| 2020 Q4 | 4.7 Million CHF | 39.38% |
| 2020 Q2 | 6.28 Million CHF | 90.49% |
| 2020 FY | 13.35 Million CHF | 18.01% |
| 2020 Q1 | 3.3 Million CHF | -45.85% |
| 2019 Q3 | 2.68 Million CHF | -45.75% |
| 2019 FY | 11.31 Million CHF | 2.6% |
| 2019 Q4 | 6.09 Million CHF | 127.5% |
| 2019 Q2 | 4.94 Million CHF | 55.03% |
| 2019 Q1 | 3.18 Million CHF | -22.48% |
| 2018 Q4 | 4.11 Million CHF | 0.0% |
| 2018 Q2 | 3.06 Million CHF | 0.0% |
| 2018 Q3 | 4.11 Million CHF | 34.22% |
| 2018 FY | 11.02 Million CHF | -2.21% |
| 2018 Q1 | 3.06 Million CHF | 26.52% |
| 2017 Q1 | 3.73 Million CHF | 116.34% |
| 2017 Q2 | 3.73 Million CHF | 0.0% |
| 2017 Q3 | 2.42 Million CHF | -35.16% |
| 2017 Q4 | 2.42 Million CHF | 0.0% |
| 2017 FY | 11.27 Million CHF | -49.68% |
| 2016 Q1 | 4.94 Million CHF | 243.63% |
| 2016 Q2 | 4.94 Million CHF | 0.0% |
| 2016 FY | 22.4 Million CHF | 336.1% |
| 2016 Q3 | 1.72 Million CHF | -65.12% |
| 2016 Q4 | 1.72 Million CHF | 0.0% |
| 2015 Q1 | 486 Thousand CHF | 0.0% |
| 2015 Q4 | 1.43 Million CHF | 0.0% |
| 2015 FY | 5.13 Million CHF | -47.76% |
| 2015 Q2 | 486 Thousand CHF | 0.0% |
| 2015 Q3 | 1.43 Million CHF | 196.19% |
| 2014 FY | 9.83 Million CHF | -59.47% |
| 2013 Q4 | 7.73 Million CHF | 28.39% |
| 2013 Q2 | 6.53 Million CHF | 64.36% |
| 2013 Q1 | 3.97 Million CHF | -6.14% |
| 2013 Q3 | 6.02 Million CHF | -7.72% |
| 2013 FY | 24.26 Million CHF | 66.26% |
| 2012 Q2 | 2.17 Million CHF | -27.1% |
| 2012 Q4 | 4.23 Million CHF | -8.04% |
| 2012 Q3 | 4.6 Million CHF | 111.73% |
| 2012 Q1 | 2.98 Million CHF | -19.84% |
| 2012 FY | 14.59 Million CHF | -31.43% |
| 2011 Q4 | 3.72 Million CHF | -49.09% |
| 2011 Q2 | 4.72 Million CHF | -14.64% |
| 2011 Q1 | 5.53 Million CHF | -7.72% |
| 2011 Q3 | 7.3 Million CHF | 54.68% |
| 2011 FY | 21.28 Million CHF | -18.8% |
| 2010 Q1 | 6.92 Million CHF | 2.14% |
| 2010 FY | 26.21 Million CHF | -27.88% |
| 2010 Q4 | 5.99 Million CHF | 2.9% |
| 2010 Q3 | 5.82 Million CHF | -21.94% |
| 2010 Q2 | 7.46 Million CHF | 7.86% |
| 2009 Q4 | 6.77 Million CHF | -5.34% |
| 2009 FY | 36.34 Million CHF | -16.66% |
| 2009 Q1 | 10.98 Million CHF | 0.0% |
| 2009 Q2 | 11.42 Million CHF | 4.0% |
| 2009 Q3 | 7.15 Million CHF | -37.34% |
| 2008 FY | 43.61 Million CHF | 56.83% |
| 2007 FY | 27.8 Million CHF | 11.05% |
| 2006 FY | 25.04 Million CHF | -25.64% |
| 2005 FY | 33.67 Million CHF | 19.04% |
| 2004 FY | 28.28 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agentix Corp. | 1.37 Million USD | -2937.202% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -726.312% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -1041.231% |
| Biomind Labs Inc. | 994.18 Thousand USD | -4090.681% |
| ContraFect Corporation | 56.88 Million USD | 26.764% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -3005.598% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1485.638% |
| CSL Limited | 3.44 Billion USD | 98.792% |
| CytoDyn Inc. | 18.05 Million USD | -130.718% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -40.977% |
| GB Sciences, Inc. | 1.42 Million USD | -2832.963% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2134.696% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1123.591% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -10594.722% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -18831.015% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 27.467% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -9927.703% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2674.021% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4411.375% |
| Skye Bioscience, Inc. | 13.54 Million USD | -207.532% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -11.83% |
| SQZ Biotechnologies Company | 85.61 Million USD | 51.339% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1933.626% |
| Zenith Capital Corp. | 8.94 Million USD | -365.873% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 51.993% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1328.657% |
| Mesoblast Limited | 5.9 Million USD | -605.913% |
| Marizyme, Inc. | 19.23 Million USD | -116.546% |
| Genus plc | 147.7 Million USD | 71.792% |
| Pharming Group N.V. | 225.49 Million USD | 81.523% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -399.616% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2717.443% |
| IMV Inc. | 37.7 Million USD | -10.485% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1393.106% |
| MultiCell Technologies, Inc. | 567.42 USD | -7342432.868% |
| ONE Bio Corp. | 6.44 Million USD | -546.55% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 51.524% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -68.574% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -2267.649% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -520.168% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 166752.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -160.227% |
| Alpha Cognition Inc. | 9.7 Million USD | -329.268% |
| Enzolytics Inc. | 2.17 Million USD | -1811.579% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 97.283% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3890.709% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1632.397% |
| Genscript Biotech Corporation | 825.34 Million USD | 94.952% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -747.168% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -15818.556% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1596.848% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -24192.02% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -2068.924% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -374.563% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -845.024% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -1012.075% |
| Helix BioMedix, Inc. | 1.97 Million USD | -2012.692% |
| EV Biologics, Inc. | 531.96 Thousand USD | -7731.95% |
| Q BioMed Inc. | 3.43 Million USD | -1112.322% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -283.39% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 58.056% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -81.342% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -2170.346% |
| HST Global, Inc. | 140.9 Thousand USD | -29467.729% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -3019.817% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -3603.674% |
| Halberd Corporation | 74.84 Thousand USD | -55567.94% |
| Resverlogix Corp. | 12.71 Million USD | -227.745% |
| Cell Source, Inc. | 4.32 Million USD | -863.229% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2537.976% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -469.925% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -239053.895% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -1588.976% |
| Kadimastem Ltd | 2.41 Million USD | -1628.675% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -882.986% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -22856.718% |
| LadRx Corporation | 3.81 Million USD | -993.003% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4411.375% |
| Affymax, Inc. | 39.38 Million USD | -5.781% |
| Itoco Inc. | 919.14 Thousand USD | -4432.809% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -3623.235% |
| Mobile Lads Corp. | 554.54 Thousand USD | -7412.993% |
| International Stem Cell Corporation | 5.27 Million USD | -690.419% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -990.612% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -165432.997% |
| Qrons Inc. | 643.67 Thousand USD | -6372.656% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2834.444% |
| SYBLEU INC | 160.87 Thousand USD | -25797.586% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1768.397% |
| Rebus Holdings, Inc. | 664 Thousand USD | -6174.548% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -2193.814% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -79044.029% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -204702.635% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -14.882% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -2474.969% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -5562.003% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1239.216% |
| Neutra Corp. | 243.82 Thousand USD | -16987.536% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -138.661% |
| PureTech Health plc | 144.59 Million USD | 71.187% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -103.334% |
| IXICO plc | 4.7 Million USD | -785.129% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -373.605% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 64.617% |
| CSL Limited | 3.89 Billion USD | 98.93% |
| Cellectis S.A. | 97.32 Million USD | 57.19% |